©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Feb 6, 2019; 7(3): 382-388
Published online Feb 6, 2019. doi: 10.12998/wjcc.v7.i3.382
Published online Feb 6, 2019. doi: 10.12998/wjcc.v7.i3.382
Considerations for routine coagulation monitoring with rivaroxaban: A case report and review of the literature
Hai-Di Wu, Hong-Yan Cao, Zi-Kai Song, Shuo Yang, Ming-Long Tang, Yang Liu, Ling Qin, Department of Cardiology, First Hospital of Jilin University, Changchun 130031, Jilin Province, China
Author contributions: All the authors contributed to the work reported in the manuscript.
Informed consent statement: The patient provided informed consent.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest.
Corresponding author: Ling Qin, MD, PhD, Professor, Department of Cardiology, First Hospital of Jilin University, 3302 Jilin Street, Changchun 130031, Jilin Province, China. qinling1958@163.com
Telephone: +86-431-84808228 Fax: +86-431-84841049
Received: September 22, 2018
Peer-review started: September 23, 2018
First decision: November 14, 2018
Revised: December 4, 2018
Accepted: December 21, 2018
Article in press: December 21, 2018
Published online: February 6, 2019
Processing time: 125 Days and 12.7 Hours
Peer-review started: September 23, 2018
First decision: November 14, 2018
Revised: December 4, 2018
Accepted: December 21, 2018
Article in press: December 21, 2018
Published online: February 6, 2019
Processing time: 125 Days and 12.7 Hours
Core Tip
Core tip: Guidelines recommend that patients treated with non-vitamin K antagonist oral anticoagulants do not require coagulation monitoring and show that routine coagulation tests generally do not provide an accurate assessment of effects and bleeding for rivaroxaban. However, our case indicates that in real-world situations, a small number of patients may develop changes in prothrombin time, international normalized ratio, and activated partial thromboplastin time with bleeding during rivaroxaban therapy. The results of literature review suggest that routine coagulation assays may be required in special populations including elderly patients, particularly low-weight females or those with renal insufficiency during oral rivaroxaban.